These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11361897)

  • 1. NIH launches interleukin-2 study.
    AIDS Patient Care STDS; 1998 Jan; 12(1):68. PubMed ID: 11361897
    [No Abstract]   [Full Text] [Related]  

  • 2. New vaccine+HAART treatment trial enrolling at NIH. National Institutes of Health.
    James JS
    AIDS Treat News; 1998 Aug; (No 300):3-4. PubMed ID: 11365687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-2 study results in confusion.
    TreatmentUpdate; 1999 Jul; 11(5):4-6. PubMed ID: 11366929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials.
    Posit Aware; 1997; 8(5):24. PubMed ID: 11364635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 in HIV infection.
    Minor JR
    Am J Health Syst Pharm; 1995 Jun; 52(12):1345-6. PubMed ID: 7656123
    [No Abstract]   [Full Text] [Related]  

  • 6. HAART and IL-2.
    AIDS Patient Care STDS; 2001 Jan; 15(1):54. PubMed ID: 11265652
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of multidrug resistant primary HIV infection with delayed CD4 T-cell count decline despite low viral load, treated with interleukin-2.
    Pao D; Smit E; Imami N; Fisher M
    AIDS; 2006 Jul; 20(11):1564-5. PubMed ID: 16847417
    [No Abstract]   [Full Text] [Related]  

  • 8. Increasing CD4 count with interleukin-2 does not benefit people with HIV.
    Roehr B
    BMJ; 2009 Feb; 338():b615. PubMed ID: 19218320
    [No Abstract]   [Full Text] [Related]  

  • 9. IL-2 plus HAART reduces HIV in immune system "hiding places".
    WORLD; 1998 Dec; (No 92):7. PubMed ID: 11365976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2: trials and tribulations.
    Kuritzkes DR
    J Infect Dis; 2009 Jul; 200(2):164-5. PubMed ID: 19508158
    [No Abstract]   [Full Text] [Related]  

  • 11. Volunteers wanted to study HIV treatments.
    Posit Aware; 1997; 8(3):14. PubMed ID: 11364418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panels to develop standards for antiviral therapy, viral-load testing.
    AIDS Alert; 1997 Feb; 12(2):13-5. PubMed ID: 11364029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NIH: weekly cycles of once-daily ARVs feasible.
    IAPAC Mon; 2004 Jun; 10(6):191. PubMed ID: 15484370
    [No Abstract]   [Full Text] [Related]  

  • 14. IL-2 therapy provides no clinical benefit to HIV-infected patients on ART.
    Clin Infect Dis; 2009 Apr; 48(8):iii. PubMed ID: 19301459
    [No Abstract]   [Full Text] [Related]  

  • 15. Improved treatment results with interleukin-2.
    HIV Hotline; 1998 May; 8(2):13-4. PubMed ID: 11365363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-2 without antiretroviral therapy, trial near Wash. D.C.
    AIDS Treat News; 1998 Mar; (No 290):7. PubMed ID: 11365122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Response and NIH begin pediatric clinical trial of Remune HIV therapy. National Institutes of Health.
    J Int Assoc Physicians AIDS Care; 1996 Jul; 2(7):44. PubMed ID: 11363748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Lunch and learn" with Dr. Melanie Thompson sheds light on IL2.
    Wilder TL
    Surviv News (Atlanta Ga); 2001 Aug; ():12-3. PubMed ID: 11682743
    [No Abstract]   [Full Text] [Related]  

  • 19. Interleukin 2 and HIV RNA Levels.
    Go R; Steigbigel R
    Arch Intern Med; 2007 Oct; 167(19):2144-5; author reply 2145. PubMed ID: 17954814
    [No Abstract]   [Full Text] [Related]  

  • 20. AIDS drugs. NIH urged to determine best start time for ARVs.
    AIDS Policy Law; 2007 Jan; 22(2):1. PubMed ID: 17319010
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.